Researchers at the University of Oxford in the UK have commenced enrolment of healthy volunteers for a clinical trial of the Covid-19 vaccine candidate ChAdOx1 nCoV-19.
The vaccine is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein. It is currently in production at the university’s Clinical Biomanufacturing Facility and is expected to be ready in the coming weeks.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial is designed to enrol up to 510 participants aged 18 to 55 and is being conducted by the university’s Jenner Institute and Oxford Vaccine Group.
